Compass Therapeutics, Inc. (CMPX) Stock Grade

About Compass Therapeutics, Inc.'s fundamentals

Compass Therapeutics is a biotechnology company with a market capitalization of $846.8 million that is currently unprofitable, having reported a net loss in its latest annual statement with a net margin of 0.0%. The company's revenue declined 100% year-over-year, indicating it is not currently generating commercial revenue. Traditional valuation metrics like P/E ratio and return on equity are not applicable due to the company's loss-making status, and the company does not pay a dividend.